{"id":21627,"date":"2024-07-25T17:23:12","date_gmt":"2024-07-25T11:53:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=21627"},"modified":"2024-07-30T12:03:01","modified_gmt":"2024-07-30T06:33:01","slug":"competitive-analysis-of-celmods-and-revlimid","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid","title":{"rendered":"CELMoDs \u2013 A Worthy Successor to REVLIMID?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69dcd52396641\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69dcd52396641\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid\/#Generic_competition_to_REVLIMID\" >Generic competition to REVLIMID<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid\/#The_arrival_of_CELMODS_and_mechanistic_differences_between_CELMODs_and_IMiDs\" >The arrival of CELMODS and mechanistic differences between CELMODs and IMiDs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid\/#Future_of_CELMODs\" >Future of CELMODs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><strong>treatment of adult patients with multiple myeloma<\/strong><\/a>, in combination with dexamethasone.&nbsp;<\/p>\n\n\n\n<p>As the wise say, no journey is smooth. Even REVLIMID\u2019s journey has had its fair share of lows, including high prices, limited accessibility, and the recent patent expiry. Despite these challenges, <a href=\"https:\/\/www.delveinsight.com\/report-store\/revlimid-api-insights\"><strong>REVLIMID<\/strong><\/a> has turned out to be a major blockbuster in multiple myeloma and is still unbeaten to this day. But will REVLIMID remain unchallenged forever, or will it eventually meet its match one day? That remains to be seen.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-generic-competition-to-revlimid\"><span class=\"ez-toc-section\" id=\"Generic_competition_to_REVLIMID\"><\/span><strong>Generic competition to REVLIMID<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Generic competition is an unavoidable reality for pharmaceutical firms. Come 2022, the year of REVLIMID\u2019s patent expiry, the drug started facing generic competition from the low-cost rivals Teva and Natco.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/revlimid-api-insights\">REVLIMID<\/a>, a small molecule drug, has a 12-year patent exclusivity period. However, it took 16 years for REVLIMID\u2019s generics to reach the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><strong>multiple myeloma therapeutics market<\/strong><\/a>. One of the major reasons for this was the REMS program for REVLIMID. Celgene used the REMS program to limit its distribution due to the safety concerns associated with REVLIMID. As a result, it became difficult for generic manufacturers to get REVLIMID samples to seek FDA approval for their generic versions.<\/p>\n\n\n\n<p>However, now that the patent has expired, BMS has experienced some hiccups. REVLIMID sales dropped from USD 12.8 billion in 2021 to USD 9.98 billion in 2022. The same pattern was observed in 2023, with US revenue declining by 37%, primarily due to generic erosion and a rise in the number of patients receiving free drug products from the Bristol Myers Squibb Patient Assistance Foundation, an independent 501(c)(3) entity supported by BMS donations. Additionally, lower average net selling prices contributed to this decrease.&nbsp;<\/p>\n\n\n\n<p>Is REVLIMID&#8217;s game over? Will its legacy slowly diminish? Well, not yet. BMS is developing potential successors to REVLIMID to become the future cornerstone of <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\">multiple myeloma treatment<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"230\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-1024x230.png\" alt=\"\" class=\"wp-image-28944\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-1024x230.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-300x67.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-150x34.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-768x172.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-1536x345.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-2048x459.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/30120245\/Sales-dip-of-Revlimid-1568x352.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-arrival-of-celmods-and-mechanistic-differences-between-celmods-and-imids\"><span class=\"ez-toc-section\" id=\"The_arrival_of_CELMODS_and_mechanistic_differences_between_CELMODs_and_IMiDs\"><\/span><strong>The arrival of CELMODS and mechanistic differences between CELMODs and IMiDs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In 2021, BMS unveiled two future superstars, Iberdomide (CC-220) and Mezigdomide (CC-92480), colloquially known as the CELMODs (Cereblon E3 ligase modulator). They are not the same as other immunomodulatory medicines (IMiDs) like REVLIMID. While both IMiDs and CELMODs bind to cereblon, the known target for these classes of drugs differ in their mechanisms.Iberdomide binds to cereblon more tightly and has greater potency. The drug degrades Ikarose and Aiolos, which serve as anti-apoptotic transcription factors in multiple myeloma cells, with much greater potency than REVLIMID. The EC50 value is the testimony of the enhanced efficacy of Iberdomide as compared to REVLIMID. Moreover, Iberdomide has tumoricidal activity as opposed to the tumoristatic activity of IMiDs, even in <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-multiple-myeloma-market\">relapsed\/refractory multiple myeloma patients<\/a> who have been administered IMiDs before.<\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"624\">\n\t<colgroup>\n\t\t<col width=\"208\">\n\t\t<col width=\"208\">\n\t\t<col width=\"208\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"3\" style=\"vertical-align:top; background-color:#4472c4; padding:0px 7px 0px 7px; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">EC<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"><sub style=\"font-size:0.6em\">50<\/sub><\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"> Comparison of Iberdomide and REVLIMID<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#d9e2f3; padding:0px 7px 0px 7px; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">EC<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\"><sub style=\"font-size:0.6em\">50<\/sub><\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">* (nM)<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#d9e2f3; padding:0px 7px 0px 7px; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Ikarose<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; background-color:#d9e2f3; padding:0px 7px 0px 7px; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Aiolos<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">REVLIMID<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">67<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">87<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Iberdomide<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">1<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.5<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td colspan=\"3\" style=\"border-bottom:1px solid #000000; vertical-align:top; padding:0px 7px 0px 7px; border-top:1px solid #000000; border-right:1px solid #000000; border-left:1px solid #000000; width:208px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\">*EC<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\"><sub style=\"font-size:0.6em\">50<\/sub><\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\"> (half-maximal effective concentration): <\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\">the concentration of a drug that induces a response halfway between the baseline and maximum<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>When we talk about Mezigdomide, it can potentially degrade Aiolos compared to the blockbuster REVLIMID, courtesy of the cytotoxic capability of Mezigdomide.&nbsp;<\/p>\n\n\n\n<p>It is important to note here that these efficacy comparisons have been made based on Phase I\/II <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\"><strong>multiple myeloma clinical trials<\/strong><\/a> (NCT02773030 and NCT03374085) being carried out in heavily pretreated fourth-line or more multiple myeloma patients. Though it is still early for CELMODs, it can be concluded that we have a clear winner in CELMODs with regard to efficacy. As far as the safety profile of CELMODs is concerned, it was observed that 44.8% of the patients being administered Iberdomide in combination with dexamethasone experienced Neutropenia, compared to 75.3% of the patients who were administered Mezigdomide in combination with dexamethasone. Long-term data are still needed to comment on the safety profile of CELMODs; however, experts believe that CELMODs are safer than REVLIMID. Thus, safety issues would also be addressed by CELMODs.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>In terms of adverse events, Iberdomide differs from IMiDs. The grade 3-4 non-heme toxicity is virtually non-existent, which really speaks about the differences in chemistry and biochemistry of Iberdomide, allowing it to have great utility, both in newly diagnosed patients and even in the maintenance setting, where it seems to be much better tolerated than REVLIMID.<\/em><\/p>\n\n\n\n<p>&nbsp;\u2013 Emory School of Medicine, US<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-of-celmods\"><span class=\"ez-toc-section\" id=\"Future_of_CELMODs\"><\/span><strong>Future of CELMODs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>CELMODs are very much in the line of succession to the throne that the great REVLIMID is slowly abdicating. The most novel late-stage Phase-III EXCALIBER trial results are not expected to be out before 2026. Iberdomide is expected to launch in 2027 and achieve multibillion-dollar sales.&nbsp;<\/p>\n\n\n\n<p>In October 2023, Bristol Myers Squibb entered a clinical trial collaboration and supply agreement with Karyopharm Therapeutics Inc. to evaluate its investigational cereblon E3 ligase modulator (CELMoD) agent mezigdomide in combination with Karyopharm&#8217;s selinexor, an approved first-in-class Exportin 1 (XPO1) inhibitor, and dexamethasone in patients with relapsed\/refractory multiple myeloma.&nbsp;<\/p>\n\n\n\n<p>Furthermore, BMS has established a comprehensive <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/multiple-myeloma-newsletter\" class=\"ek-link\">multiple myeloma treatment strategy<\/a> and is quite optimistic about CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment. As the newest treatment for multiple myeloma, CELMODs represent a significant innovation with the potential to redefine therapeutic approaches. However, it remains to be seen whether CELMODs can live up to such high expectations or if they will fall short. Further trials and clinical data will be crucial in determining whether CELMODs will become the next blockbuster in the evolving landscape of multiple myeloma therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1024x194.png\" alt=\"Multiple Myeloma Market Outlook and Insights\" class=\"wp-image-28816\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/24124907\/Multiple-Myeloma-Market-Outlook-and-Insights-1.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><figcaption class=\"wp-element-caption\">Multiple Myeloma Market Outlook and Insights<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1678421138675\"><strong class=\"schema-faq-question\"><strong>1. What is multiple myeloma?<\/strong><\/strong> <p class=\"schema-faq-answer\">Multiple myeloma is a type of plasma cell cancer. Multiple myeloma is a cancerous condition in which plasma cells grow uncontrollably. Plasma cells produce an abnormal protein (antibody) known as monoclonal immunoglobulin, monoclonal protein (M-protein), Mspike, or paraprotein. Normal plasma cells are found in the bone marrow and play an important role in the immune system.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1678421150835\"><strong class=\"schema-faq-question\"><strong>2. What causes multiple myeloma?<\/strong><\/strong> <p class=\"schema-faq-answer\">The majority of researchers do not know what causes multiple myeloma. However, they have made progress in understanding how certain changes in DNA can cause plasma cells to become cancerous.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1678421163821\"><strong class=\"schema-faq-question\"><strong>3. What are the multiple myeloma symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Multiple myeloma symptoms and signs can vary, and early in the disease, there may be none. the common multiple myeloma symptoms include Bone pain, especially in the spine or chest, nausea, constipation, loss of appetite, mental fogginess or confusion, fatigue, frequent infections, weight loss, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1678421179021\"><strong class=\"schema-faq-question\"><strong>4. What are the current multiple myeloma treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">Multiple myeloma treatment typically includes anti-myeloma medications to destroy myeloma cells or control cancer when it recurs (relapses), as well as medications and procedures to prevent and treat complications caused by myeloma, such as bone pain, fractures, and anemia. The main multiple myeloma treatment options are stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1678421190895\"><strong class=\"schema-faq-question\"><strong>5. How many therapies are in development for multiple myeloma treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key players, such as AbbVie\/Roche (Venetoclax), Janssen Research &amp; Development (Teclistamab), Regeneron Pharmaceuticals (REGN5458), Bristol-Myers Squibb\/Celgene (Iberdomide), Cartesian Therapeutics (Descartes-11), and others, are involved in developing drugs for multiple myeloma treatment.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.&nbsp; As the wise say, no journey is smooth. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":21630,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":4,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[20463,410,2833,16669,19906,16672,518],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-21627","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-celmods","tag-multiple-myeloma","tag-multiple-myeloma-drugs-market","tag-multiple-myeloma-market","tag-multiple-myeloma-treatment","tag-multiple-myeloma-treatment-market","tag-revlimid","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Analysis of CELMoDs and REVLIMID in Multiple Myeloma<\/title>\n<meta name=\"description\" content=\"BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analysis of CELMoDs and REVLIMID in Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-25T11:53:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-30T06:33:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/10094319\/competitive-analysis-of-celmods-and-revlimid.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Analysis of CELMoDs and REVLIMID in Multiple Myeloma","description":"BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid","og_locale":"en_US","og_type":"article","og_title":"Analysis of CELMoDs and REVLIMID in Multiple Myeloma","og_description":"BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.","og_url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-07-25T11:53:12+00:00","article_modified_time":"2024-07-30T06:33:01+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/10094319\/competitive-analysis-of-celmods-and-revlimid.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid","url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid","name":"Analysis of CELMoDs and REVLIMID in Multiple Myeloma","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/10094319\/competitive-analysis-of-celmods-and-revlimid.png","datePublished":"2024-07-25T11:53:12+00:00","dateModified":"2024-07-30T06:33:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"BMS has established a comprehensive treatment strategy, with CELMODs replacing REVLIMID in earlier lines of multiple myeloma treatment.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421138675"},{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421150835"},{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421163821"},{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421179021"},{"@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421190895"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/10094319\/competitive-analysis-of-celmods-and-revlimid.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/10094319\/competitive-analysis-of-celmods-and-revlimid.png","width":772,"height":482,"caption":"competitive-analysis-of-celmods-and-revlimid"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421138675","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421138675","name":"1. What is multiple myeloma?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Multiple myeloma is a type of plasma cell cancer. Multiple myeloma is a cancerous condition in which plasma cells grow uncontrollably. Plasma cells produce an abnormal protein (antibody) known as monoclonal immunoglobulin, monoclonal protein (M-protein), Mspike, or paraprotein. Normal plasma cells are found in the bone marrow and play an important role in the immune system.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421150835","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421150835","name":"2. What causes multiple myeloma?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The majority of researchers do not know what causes multiple myeloma. However, they have made progress in understanding how certain changes in DNA can cause plasma cells to become cancerous.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421163821","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421163821","name":"3. What are the multiple myeloma symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Multiple myeloma symptoms and signs can vary, and early in the disease, there may be none. the common multiple myeloma symptoms include Bone pain, especially in the spine or chest, nausea, constipation, loss of appetite, mental fogginess or confusion, fatigue, frequent infections, weight loss, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421179021","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421179021","name":"4. What are the current multiple myeloma treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Multiple myeloma treatment typically includes anti-myeloma medications to destroy myeloma cells or control cancer when it recurs (relapses), as well as medications and procedures to prevent and treat complications caused by myeloma, such as bone pain, fractures, and anemia. The main multiple myeloma treatment options are stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421190895","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/competitive-analysis-of-celmods-and-revlimid#faq-question-1678421190895","name":"5. How many therapies are in development for multiple myeloma treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key players, such as AbbVie\/Roche (Venetoclax), Janssen Research &amp; Development (Teclistamab), Regeneron Pharmaceuticals (REGN5458), Bristol-Myers Squibb\/Celgene (Iberdomide), Cartesian Therapeutics (Descartes-11), and others, are involved in developing drugs for multiple myeloma treatment.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/03\/10094319\/competitive-analysis-of-celmods-and-revlimid-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CELMoDs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Revlimid<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CELMoDs<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Revlimid<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jul 25, 2024","modified":"Updated on Jul 30, 2024"},"absolute_dates_time":{"created":"Posted on Jul 25, 2024 5:23 pm","modified":"Updated on Jul 30, 2024 12:03 pm"},"featured_img_caption":"competitive-analysis-of-celmods-and-revlimid","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=21627"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21627\/revisions"}],"predecessor-version":[{"id":28946,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/21627\/revisions\/28946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/21630"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=21627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=21627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=21627"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=21627"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=21627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}